NEWTOWN -
Presentation Details
Date/Time:
Speaker:
1X1 meetings: The Onconova Management Team will be available for 1X1 meetings during the conference. Those interested in requesting a meeting should contact their
A webcast of the presentation will be available the following day on the 'Corporate Events and Presentations' section of the Onconova website, and as part of a complete catalog of presentations available at
About
Narazaciclib, Onconova's novel, multi-kinase inhibitor (formerly ON 123300), is being evaluated in a Phase 1/2 combination trial with the estrogen blocker letrozole, in advanced endometrial cancer (NCT05705505). Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova believes narazaciclib has broad potential and is also evaluating opportunities for combination studies with narazaciclib and letrozole in additional indications, including breast cancer, ovarian cancer and mantle cell lymphoma.
Rigosertib is being studied in an investigator-sponsored trial strategy to evaluate the product candidate in multiple indications, including a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer (NCT04263090), a Phase 2 program evaluating oral or IV rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) (NCT03786237, NCT04177498), and a Phase 2 trial evaluating rigosertib in combination with pembrolizumab in patients with metastatic melanoma.
Contact:
Tel: 267-759-3680
Email: ir@onconova.us
Web: https://www.onconova.com
Tel: 646-889-1200
Email: bmackle@lifesciadvisors.com
(C) 2023 Electronic News Publishing, source